STOCK TITAN

Coastlands entities hold 2.39M shares in Pasithea Therapeutics (NASDAQ: KTTA)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Pasithea Therapeutics Corp. reports Coastlands-affiliated filers hold 2,394,765 shares, representing 9.99% of common stock. The reported position consists of 1,514,199 shares held directly and 880,566 shares issuable upon exercise of pre-funded warrants, calculated using 23,091,062 shares outstanding as of December 22, 2025. The filing shows shared voting and dispositive power over the 2,394,765 shares and states the 9.99% beneficial ownership limitation applies to the warrants.

The filing is submitted jointly by Coastlands Capital entities and Matthew D. Perry, who is identified as a control person; each reporting person disclaims membership in a group and disclaims beneficial ownership except to the extent of pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

Coastlands-affiliated entities report a 9.99% stake via direct shares and exercisable pre-funded warrants.

The filing documents shared voting and dispositive power over 2,394,765 shares, comprised of 1,514,199 directly held shares and 880,566 shares issuable upon exercise of pre-funded warrants, measured against 23,091,062 shares outstanding as of December 22, 2025. The disclosure includes a stated beneficial ownership limitation of 9.99% that caps the included warrant exercises.

Future activity will depend on holder decisions and warrant exercise mechanics; subsequent filings would show any change in voting power or percent ownership.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Consists of 1,514,199 shares of Common Stock held directly by Coastlands Capital LP and 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP. The calculation of the beneficial ownership of the Reporting Persons is based on (A) 23,091,062 shares outstanding as December 22, 2025, as disclosed in the definitive proxy statement on DEF 14A filed by the Issuer on December 29, 2025 and (B) 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation.


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of 1,514,199 shares of Common Stock held directly by Coastlands Capital LP and 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP. The calculation of the beneficial ownership of the Reporting Persons is based on (A) 23,091,062 shares outstanding as December 22, 2025, as disclosed in the definitive proxy statement on DEF 14A filed by the Issuer on December 29, 2025 and (B) 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation.


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of 1,514,199 shares of Common Stock held directly by Coastlands Capital LP and 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP. The calculation of the beneficial ownership of the Reporting Persons is based on (A) 23,091,062 shares outstanding as December 22, 2025, as disclosed in the definitive proxy statement on DEF 14A filed by the Issuer on December 29, 2025 and (B) 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation.


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of 1,514,199 shares of Common Stock held directly by Coastlands Capital LP and 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP. The calculation of the beneficial ownership of the Reporting Persons is based on (A) 23,091,062 shares outstanding as December 22, 2025, as disclosed in the definitive proxy statement on DEF 14A filed by the Issuer on December 29, 2025 and (B) 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation.


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of 1,514,199 shares of Common Stock held directly by Coastlands Capital LP and 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by Coastlands Capital LP. The calculation of the beneficial ownership of the Reporting Persons is based on (A) 23,091,062 shares outstanding as December 22, 2025, as disclosed in the definitive proxy statement on DEF 14A filed by the Issuer on December 29, 2025 and (B) 880,566 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Persons, which reflects the beneficial ownership limitation of 9.99%. Excludes pre-funded warrants held by the Reporting Persons in excess of such beneficial ownership limitation.


SCHEDULE 13G



Coastlands Capital LP
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer of the General Partner, Coastlands Capital LLC
Date:02/27/2026
Coastlands Capital Partners LP
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer of the General Partner, Coastlands Capital GP LLC
Date:02/27/2026
Coastlands Capital GP LLC
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer
Date:02/27/2026
Coastlands Capital LLC
Signature:/s/ Mark Shamia
Name/Title:Chief Operating Officer
Date:02/27/2026
Matthew D. Perry
Signature:/s/ Matthew D. Perry
Name/Title:Reporting Person
Date:02/27/2026

Comments accompanying signature: Exhibit 99.1 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

FAQ

What stake does Coastlands report in Pasithea Therapeutics (KTTA)?

Coastlands-affiliated filers report beneficial ownership of 2,394,765 shares, equal to 9.99% of common stock, based on 23,091,062 shares outstanding as of December 22, 2025. This includes direct shares and exercisable pre-funded warrants.

How is the 2,394,765-share position composed for KTTA?

The position consists of 1,514,199 shares held directly and 880,566 shares issuable upon exercise of pre-funded warrants, with the filing applying a 9.99% beneficial ownership limitation to those warrants.

Who are the reporting persons for the KTTA Schedule 13G filing?

The filing is made jointly by Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry, with Mr. Perry identified as the control person of those entities.

What voting and dispositive power do the Coastlands filers report for KTTA?

The reporting persons state they have shared voting power and shared dispositive power over 2,394,765 shares; they report no sole voting or sole dispositive power for those shares.
Pasithea Therapeutics Corp

NASDAQ:KTTA

KTTA Rankings

KTTA Latest News

KTTA Latest SEC Filings

KTTA Stock Data

19.34M
22.72M
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI BEACH